English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Choriocarcinoma is a gestational trophoblastic tumor and also a germ cell tumor that mainly affects women of childbearing age and rarely occurs in postmenopausal women especially following a long latent period from previous pregnancies. Since choriocarcinoma is absolutely sensitive to chemotherapy, the cure rate even for metastatic choriocarcinoma is around 90-95%. At present, treatment with single-agent methotrexate is recommended for low-risk disease, while intense combination chemotherapy agents including EMACO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine) are recommended for the intermediate or high-risk disease. If the germ cell tumors are relapsed or refractory to the salvage chemotherapy, autologous hematopoietic stem cell transplantation (AHSCT) can be used for the treatment like lymphoproliferative diseases and sarcomas (1,2).

Primary vulvovaginal choriocarcinoma patient who underwent autologous hematopoetic stem cell transplantation: A case report of unusual presentation